Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6304785 | 0.90 | CHRNA7 (0.57) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6305741 | 0.89 | CHRNA7 (0.55) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6303422 | 0.89 | CHRNA7 (0.68) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6310439 | 0.89 | CHRNA7 (0.54) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6303392 | 0.89 | CHRNA7 (0.54) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6310482 | 0.88 | CHRNA7 (0.53) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6306752 | 0.87 | CHRNA7 (0.53) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6305831 | 0.87 | CHRNA7 (0.53) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6306915 | 0.85 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6309860 | 0.85 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | CHRNA7 2937/4885HTR3E 1662/4885HTR3B 1018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.